ASCO 2019 | Second generation BTK-inhibitors for CLL
Susan O’Brien
• 1 Jun 2019
BTK-inhibitors present a good option for many CLL patients. Susan O’Brien, MD, of the University of California Irvine, Irvine, CA, discusses the use of BTK-inhibitors for chronic lymphocytic leukemia and which she believes are most clinically relevant. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
